Related Experiment Video
Updated: Jan 21, 2026

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
Published on: August 25, 2023
[Outcome studies on SGLT-2 inhibitors]
1Abteilung Endokrinologie und Diabetologie, Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Medizinische Fakultät, Universität Freiburg, Hugstetter Straße 55, 79106, Freiburg, Deutschland. jochen.seufert@uniklinik-freiburg.de.
Background:
Inhibitors of sodium-glucose cotransporters type 2 (SGLT-2) are a class of oral antidiabetic drugs with a novel specific mode of action in the kidneys.
Objective:
The effects of SGLT-2 inhibitors on cardiovascular (CV) and renal endpoints in outcome trials with type 2 diabetes patients.
Material And Methods:
Differential analysis and interpretation of the results of outcome trials with the SGLT-2 inhibitors empagliflozin, canagliflozin and dapagliflozin in type 2 diabetes mellitus.
Results:
In the EMPA-REG OUTCOME trial, empagliflozin demonstrated a significant reduction in major cardiac adverse events (MACE), hospitalization for heart failure (HHI), renal endpoints, CV and total mortality vs. placebo in >7000 patients with type 2 diabetes and established CV disease over 3.1 years. In the CANVAS program, canagliflozin demonstrated a significant reduction of MACE, HHI and renal endpoints vs. placebo in >10,000 patients with type 2 diabetes and high CV risk over 2.4 years. In the CREDENCE trial, canagliflozin demonstrated a significant reduction of a combined renal endpoint and CV endpoints vs. placebo in >4000 patients with type 2 diabetes and established kidney disease with albuminuria over 2.6 years. In the DECLARE-TIMI 58 trial, dapagliflozin demonstrated a significant reduction in a combined endpoint of CV death and HHI vs. placebo in >17,000 patients with type 2 diabetes and established CV disease or with multiple CV risk factors over 3.1 years.
Conclusion:
Outcome trials with SGLT-2 inhibitors have collectively demonstrated cardioprotective and nephroprotective effects in patients with type 2 diabetes and high CV risk. The use of SGLT-2 inhibitors is recommended in current guidelines and consensus statements as primary combination partners for metformin in patients with type 2 diabetes and established CV disease, high CV risk, heart failure or kidney disease.
Insights
Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors show significant cardiovascular and renal benefits in type 2 diabetes patients. These drugs are recommended for patients with established cardiovascular disease, heart failure, or kidney disease.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors represent a novel class of oral antidiabetic drugs.
- These drugs exert a unique mechanism of action within the kidneys to manage blood glucose levels.
Purpose of the Study:
- To evaluate the cardiovascular (CV) and renal effects of SGLT-2 inhibitors.
- Analysis focused on outcome trials involving patients with type 2 diabetes.
Main Methods:
- Differential analysis and interpretation of results from major SGLT-2 inhibitor outcome trials.
- Key drugs analyzed include empagliflozin, canagliflozin, and dapagliflozin in type 2 diabetes mellitus patients.
Main Results:
- Empagliflozin in EMPA-REG OUTCOME significantly reduced MACE, heart failure hospitalizations, renal endpoints, and mortality.
- Canagliflozin in CANVAS and CREDENCE trials demonstrated significant reductions in MACE, heart failure hospitalizations, and renal endpoints.
- Dapagliflozin in DECLARE-TIMI 58 showed significant reductions in a composite of CV death and heart failure hospitalization.
Conclusions:
- SGLT-2 inhibitor outcome trials collectively demonstrate cardioprotective and nephroprotective benefits.
- These benefits are evident in type 2 diabetes patients with high CV risk.
- Current guidelines recommend SGLT-2 inhibitors as primary partners with metformin for specific patient groups.
More Related Videos
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Dipeptidyl Peptidase 4 Inhibitors
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H

